Quick Answer
Forte Biosciences, Inc. reported R&D Expense of $45.30 million for fiscal year 2019.
Forte Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2019 | $45.30M | -11.3% |
| 2018 | $51.08M | +75.5% |
| 2017 | $29.11M | +7.0% |
| 2016 | $27.22M | +42.0% |
| 2015 | $19.17M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2020 | $3.14M | -74.7% | -76.4% |
| September 30, 2019 | $13.29M | +8.4% | +11.0% |
| June 30, 2019 | $11.97M | -6.2% | -3.7% |
| March 31, 2019 | $12.43M | +19.1% | +1.4% |
| September 30, 2018 | $12.26M | +62.1% | -3.9% |
| June 30, 2018 | $12.76M | +92.4% | +22.3% |
| March 31, 2018 | $10.44M | +57.5% | +38.0% |
| September 30, 2017 | $7.56M | -0.3% | +14.0% |
- Forte Biosciences, Inc. showed a decrease of -11.3% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2019 period, Forte Biosciences, Inc.’s r&d expense has grown by 136.3% (from $19.17 million to $45.30 million).
- The most recent figure is from Forte Biosciences, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on February 27, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: